About Daan Biotherapeutics
Daan Biotherapeutics is a company based in Seoul (South Korea) founded in 2020 by J Y Han.. Daan Biotherapeutics has raised $17.21 million across 1 funding round from investors including Shinhan Financial Group, Atinum Investment and KB Investment. Daan Biotherapeutics operates in a competitive market with competitors including Genprex, Bridge Biotherapeutics, Lineage Cell Therapeutics, Xcovery and Flame Biosciences, among others.
- Headquarter Seoul, South Korea
- Founders J Y Han
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$17.21 M (USD)
in 1 rounds
-
Latest Funding Round
$17.21 M (USD), Series A
Jan 27, 2024
-
Investors
Shinhan Financial Group
& 10 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Daan Biotherapeutics
Daan Biotherapeutics has successfully raised a total of $17.21M through 1 strategic funding round. The most recent funding activity was a Series A round of $17.21 million completed in January 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series A — $17.2M
-
First Round
First Round
(27 Jan 2024)
- Investors Count 11
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2024 | Amount | Series A - Daan Biotherapeutics | Valuation | Solasta Ventures , Company K Partners |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Daan Biotherapeutics
Daan Biotherapeutics has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include Shinhan Financial Group, Atinum Investment and KB Investment. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on healthcare startups
|
Founded Year | Domain | Location | |
|
Venture capital firm investing in tech startups
|
Founded Year | Domain | Location | |
|
Strategic investments are made in high-growth companies by Paratus Investment.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Daan Biotherapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Daan Biotherapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Daan Biotherapeutics Comparisons
Competitors of Daan Biotherapeutics
Daan Biotherapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Genprex, Bridge Biotherapeutics, Lineage Cell Therapeutics, Xcovery and Flame Biosciences, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for molecular-level cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics are developed for treating various diseases.
|
|
| domain | founded_year | HQ Location |
Lineage Cell Therapeutics is focused on developing allogeneic cell therapies.
|
|
| domain | founded_year | HQ Location |
Kinase inhibitors are developed for non-small cell lung cancer treatment.
|
|
| domain | founded_year | HQ Location |
Inflammation-driven cancer and disease drugs are manufactured.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Daan Biotherapeutics
Frequently Asked Questions about Daan Biotherapeutics
When was Daan Biotherapeutics founded?
Daan Biotherapeutics was founded in 2020 and raised its 1st funding round 4 years after it was founded.
Where is Daan Biotherapeutics located?
Daan Biotherapeutics is headquartered in Seoul, South Korea.
Who is the current CEO of Daan Biotherapeutics?
Byoung Chul Cho is the current CEO of Daan Biotherapeutics.
Is Daan Biotherapeutics a funded company?
Daan Biotherapeutics is a funded company, having raised a total of $17.21M across 1 funding round to date. The company's 1st funding round was a Series A of $17.21M, raised on Jan 27, 2024.
What does Daan Biotherapeutics do?
Daan Biotherapeutics was founded in 2020 in Seoul, South Korea. Operations are centered in the biotechnology sector, where therapeutics for cancer treatment are developed. Immune-based cell therapies are focused on lung cancer, with T Cell Receptors (TCR) derived from natural killer cells used to target EGFR mutations. The company is led by founder J Y Han and CEO Byoung Chul Cho.
Who are the top competitors of Daan Biotherapeutics?
Daan Biotherapeutics's top competitors include Genprex, Lineage Cell Therapeutics and Xcovery.
Who are Daan Biotherapeutics's investors?
Daan Biotherapeutics has 11 investors. Key investors include Shinhan Financial Group, Atinum Investment, KB Investment, Company K Partners, and Solasta Ventures.